FDA To Review Merck's Application To Expand HPV Vaccine Gardasil's Approval To Older Women

Main Category: Cervical Cancer / HPV Vaccine
Also Included In: Regulatory Affairs / Drug Approvals;  Women's Health / Gynecology
Article Date: 24 Mar 2008 - 5:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:5 stars

5 (3 votes)


FDA has granted priority review status to Merck's application to expand marketing of its human papillomavirus vaccine Gardasil to women ages 27 to 45, the company said Wednesday, Reuters reports. The designation means that an FDA decision could come within six months, according to Reuters. currently is approved by the FDA for use by girls and women ages nine to 26 (Reuters, 3/19).

Gardasil in clinical trials has been shown to prevent infection with HPV strains 16 and 18, which together cause about 70% of cervical cancer cases, and to prevent infection with HPV strains 6 and 11, which cause about 90% of genital warts cases (Daily Women's Health Policy Report, 2/7). FDA is expected to make a decision on the application within six months, rather than the typical 10 months, according to Reuters (Reuters, 3/19).

In the application, Merck noted that women are at risk of HPV throughout their lives. Merck spokesperson Kelley Dougherty said that because researchers have found few women are infected with all four HPV types that the vaccine protects against, Gardasil would prevent women infected with one or more of the strains from contracting the others. She added that there are no commercial tests currently available to differentiate among the strains of HPV (AP/San Diego Union-Tribune, 3/19).

Seamus Fernandez, an analyst at Leerink Swann, said the priority review status is a positive surprise. He added that he anticipates a "straightforward" review of the application because of the lack of serious side effects among women who received the vaccine in clinical trials (Reuters, 3/19).

Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.

© 2007 The Advisory Board Company. All rights reserved.

View drug information on Gardasil.


Article adapted by Medical News Today from original press release.
Visit our cervical cancer / hpv vaccine section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
National Partnership for Women & Families. "FDA To Review Merck's Application To Expand HPV Vaccine Gardasil's Approval To Older Women." Medical News Today. MediLexicon, Intl., 24 Mar. 2008. Web.
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/101354.php>

APA
National Partnership for Women & Families. (2008, March 24). "FDA To Review Merck's Application To Expand HPV Vaccine Gardasil's Approval To Older Women." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/101354.php.

Please note: If no author information is provided, the source is cited instead.


Cervical Cancer / HPV Vaccine

Most Popular Articles



Follow Our Cervical Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cervical Cancer / HPV Vaccine Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »